The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
Open accessAbstract
mRNA vaccines have the potential to tackle many unmet medical needs that are unable to be addressed with conventional vaccine technologies. A potent and well-tolerated delivery technology is integral to fully realizing the potential of mRNA vaccines. Pre-clinical and clinical studies have demonstrated that mRNA delivered intramuscularly (IM) with first-generation lipid nanoparticles (LNPs) generates robust immune responses. Despite progress made over the past several years, there remains significant opportunity for improvement, as the most advanced LNPs were designed for intravenous (IV) delivery of siRNA to the liver. Here, we screened a panel of proprietary biodegradable ionizable lipids for both expression and immunogenicity in a rodent model when administered IM. A subset of compounds was selected and further evaluated for tolerability, immunogenicity, and expression in rodents and non-human primates (NHPs). A lead formulation was identified that yielded a robust immune response with improved tolerability. More importantly for vaccines, increased innate immune stimulation driven by LNPs does not equate to increased immunogenicity, illustrating that mRNA vaccine tolerability can be improved without affecting potency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which are known to have significantly higher delivery efficiency in hepatocytes after intravenous (i.v.) injection31 or in muscle cells after intramuscular (i.m.) injection.32”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [32]
In the citing paper
“Based on these observations, Moderna has developed an ionizable lipid (namely Lipid H, SM-102), whose tail adopts larger branches which in turn increases potency, and whose introduced ester bonds increase biodegradability (Fig. 7).290,291”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [291]
In the citing paper
“All three major players in the mRNA vaccine field have previously optimized so-called lipid nanoparticles (LNPs), constructs that typically consist of an ionizable lipid and one or more helper lipids to improve LNP stability and promote endosomal escape upon cellular uptake [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“For Moderna's LNP formulation, Hassett et al. reported that the SM-102 lipid was selected based on its improved tolerability profile in non-human primates, as evidenced by a reduced local reactogenicity (e.g., edema and erythema) and lowest induction of systemic cytokine responses (e.g., IL-6) [13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“the usage of the SM-102 lipid in Moderna's mRNA-1273 vaccine was found to outperform Onpattro's MC3 LNPs for the intramuscular (i.m.) delivery of mRNA in rodents and non-human primates, given its improved tolerability and higher endosomal escape efficiency [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“Endosomal escape can be increased by optimizing the pKa values of ionizable lipids66,76–78,88,100,140.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
In the citing paper
“To improve the biocompatibility of lipid nanoparticles, biodegradable lipids can be applied76–78,108,179.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
In the citing paper
“Moreover, the delivery efficacy of mRNA could be improved, for example, by rational design of lipids through modulation of head groups and hydrophobic tails to increase cellular uptake and endosomal escape of lipid nanoparticle–mRNA formulations64,66,76–78,88,97,100,114,140,141.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
Lanciotti, R. S., Kosoy, O. L., Laven, J. J., Velez, J. O., Lambert, A. J., Johnson, A. J., Stanfield, S. M., & Duffy, M. R. (2008) · Emerging infectious diseases · doi:10.3201/eid1408.080287 · Cited by 2,173
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×
“8.(11,13,23) However, the best lipids with respect to protein expression after IV administration generally had lower pKas than the best lipids for protein expression after IM administration.”
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Edward Jenner and the History of Smallpox and Vaccination
Riedel, S. F. (2005) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2005.11928028 · Cited by 965
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Self-citationZika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 918
Sato, S., Sano, S., Muto, H., Kubara, K., Kondo, K., Miyazaki, T., Suzuki, Y., Uemoto, Y., & Ukai, K. (2024) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c24-00089 · Cited by 34
Laila, U. E., An, W., & Xu, Z.-X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1448489 · Cited by 34
Targeted Delivery of mRNA with Polymer–Lipid Nanoparticles for In Vivo Base Editing
Chen, Q., Chang, Y., He, X., Ding, Y., Wang, R., Luo, R., Yuan, J., Chen, J., Zhong, G., Yang, H. Y., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c14041 · Cited by 34
Cell Membrane‐Coated Lipid Nanoparticles for Drug Delivery
Zewail, M. B., Yang, G., Fan, Y., Hui, Y., Zhao, C., & Liu, Y. (2025) · Aggregate · doi:10.1002/agt2.70054 · Cited by 34
High-Throughput Automation of Endosomolytic Polymers for mRNA Delivery
Ulkoski, D., Munson, M. J., Jacobson, M. E., Palmer, C. R., Carson, C. S., Sabirsh, A., Wilson, J. T., & Krishnamurthy, V. R. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01463 · Cited by 34
Stabilin-1 is required for the endothelial clearance of small anionic nanoparticles
Arias‐Alpizar, G., Koch, B. E. V., Hamelmann, N. M., Neustrup, M. A., Paulusse, J. M. J., Jiskoot, W., Kros, A., & Bussmann, J. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102395 · Cited by 34
Hengelbrock, A., Schmidt, A., & Strube, J. (2023) · Processes · doi:10.3390/pr11061718 · Cited by 33
Kinetics of RNA-LNP delivery and protein expression
Müller, J., Schäffler, N. G., Kellerer, T., Schwake, G., Ligon, T. S., & Rädler, J. O. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114222 · Cited by 35
Maltseva, M., Keeshan, A., Cooper, C., & Langlois, M. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2384192 · Cited by 34
Lian, Z., Zheng, L., Liu, S., Zhang, J., Zhou, J. J., Wu, J., Ouyang, S., Li, J., & Yang, H. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c05367 · Cited by 35
Nano‐Oncologicals: A Tortoise Trail Reaching New Avenues
Dacoba, T. G., Anthiya, S., Berrecoso, G., Fernández‐Mariño, I., Fernández‐Varela, C., Crecente‐Campo, J., Teijeiro‐Osorio, D., Torres, F., & Alonso, M. J. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202009860 · Cited by 34
Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines
Abbasi, S., & Uchida, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050644 · Cited by 33
Miliotou, Α. N., Pappas, I. S., Spyroulias, G. A., Vlachaki, E., Tsiftsoglou, A. S., Vizirianakis, I. S., & Papadopoulou, L. C. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.09.008 · Cited by 33
mRNA-based modalities for infectious disease management
Zhang, M., Hussain, A., Yang, H., Zhang, J., Liang, X., & Huang, Y. (2022) · Nano Research · doi:10.1007/s12274-022-4627-5 · Cited by 35
Circular RNA vaccines: Pioneering the next-gen cancer immunotherapy
Das, U., Banerjee, S., Sarkar, M., Fathah Muhammad, L., Soni, T. K., Saha, M., Pradhan, G., & Chatterjee, B. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.11.003 · Cited by 37
Inhalable mRNA vaccines for respiratory diseases: a roadmap
Roh, E. H., Fromen, C. A., & Sullivan, M. O. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.10.017 · Cited by 32
Circular mRNA Vaccine against SARS-COV-2 Variants Enabled by Degradable Lipid Nanoparticles
Huang, K., Li, N., Li, Y., Zhu, J., Fan, Q., Yang, J., Gao, Y., Liu, Y., Gao, S., Zhao, P., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c20770 · Cited by 32
Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programed cell death
Chang, S. C., Gopal, P., Lim, S., Wei, X., Chandramohan, A., Mangadu, R., Smith, J., Ng, S., Gindy, M., Phan, U., et al. (2022) · Cell Chemical Biology · doi:10.1016/j.chembiol.2022.10.005 · Cited by 31
Elucidating the nanostructure of small interfering RNA-loaded lipidoid-polymer hybrid nanoparticles
Aljabbari, A., Lokras, A. G., Kirkensgaard, J. J. K., Rades, T., Franzyk, H., Thakur, A., Zhang, Y., & Foged, C. (2022) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2022.11.141 · Cited by 31
Use, exposure and omics characterisation of potential hazard in nanomaterials
Ling, N., Zhang, N., Yong, W. T. L., Misbah, S., Hashim, F., Soon, C. F., Lim, G. P., Peng, W., & Sonne, C. (2023) · Materials Today Advances · doi:10.1016/j.mtadv.2023.100341 · Cited by 31
Jha, S. K., Imran, M., Jha, L. A., Hasan, N., Panthi, V. K., Paudel, K. R., Almalki, W. H., Mohammed, Y., & Kesharwani, P. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116823 · Cited by 32
Path towards mRNA delivery for cancer immunotherapy from bench to bedside
Chen, W., Zhu, Y., He, J., & Sun, X. (2023) · Theranostics · doi:10.7150/thno.89247 · Cited by 33
Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics
Ou, L., Setegne, M. T., Elliot, J., Shen, F., & Dassama, L. M. K. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00595 · Cited by 33
Amoako, K. A., Mokhammad, A., Malik, A., Yesudasan, S., Wheba, A., Olagunju, O., Gu, S. X., Yarovinsky, T. O., Faustino, E. V. S., Nguyen, J., et al. (2025) · Frontiers in Medical Technology · doi:10.3389/fmedt.2025.1591119 · Cited by 31
Yu, H., Dyett, B., Kirby, N. M., Cai, X., Mohamad, M. E., Bozinovski, S., Drummond, C. J., & Zhai, J. (2024) · Small · doi:10.1002/smll.202309200 · Cited by 29
Ige, M. A., Ren, X., Yang, Y., Zhang, H., Shen, C., Jiang, Y., Li, J., & Wan, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102721 · Cited by 30
Single intramuscular injection of self-amplifying RNA of Nppa to treat myocardial infarction
Zhang, K., Tao, H., Zhu, D., Yue, Z., Hu, S., Wu, Y., Yan, N., Hu, Y., Liu, S., Liu, M., et al. (2026) · Science · doi:10.1126/science.adu9394 · Cited by 30
Nucleic acid delivery and nanoparticle design for COVID vaccines
Andresen, J. L., & Fenton, O. S. (2021) · MRS Bulletin · doi:10.1557/s43577-021-00169-2 · Cited by 32
Kolesnikov, E. S., Gushchin, I., Zhilyaev, P. A., & Onufriev, A. V. (2021) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c00332 · Cited by 31
An old problem with new solutions: Strategies to improve vaccine efficacy in the elderly
Bell, M. R., & Kutzler, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114175 · Cited by 29
Subcellular delivery of lipid nanoparticles to endoplasmic reticulum and mitochondria
Shi, Y., Luo, Z., & You, J. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1803 · Cited by 30
Formulation, design and strategies for efficient nanotechnology-based nasal delivery systems
de Barros, C. T., Portugal, I., Batain, F., Portella, D. L., Severino, P. B., Cardoso, J. C., Arcuri, P., Chaud, M. V., & Alves, T. (2022) · RPS Pharmacy and Pharmacology Reports · doi:10.1093/rpsppr/rqac003 · Cited by 29
Next-generation materials for RNA–lipid nanoparticles: lyophilization and targeted transfection
Wang, T., Sung, T., Yu, T., Lin, H.-Y., Chen, Y.-H., Zhu, Z.-W., Gong, J., Pan, J., & Higuchi, A. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00308f · Cited by 31
mRNA Vaccine Nanoplatforms and Innate Immunity
Wei, L., Dong, C., Zhu, W., & Wang, B. (2024) · Viruses · doi:10.3390/v16010120 · Cited by 28
Design and development of mRNA and self-amplifying mRNA vaccine nanoformulations
Omidi, Y., Pourseif, M. M., Ansari, R. A., & Barar, J. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2419815 · Cited by 29
Sato, Y. (2021) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c21-00705 · Cited by 29
Genetically engineered transfusable platelets using mRNA lipid nanoparticles
Leung, J., Strong, C., Badior, K. E., Robertson, M. K., Wu, X., Meledeo, M. A., Kang, E., Paul, M., Sato, Y., Harashima, H., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi0508 · Cited by 32
Biological recognition and cellular trafficking of targeted RNA-lipid nanoparticles
Escalona-Rayo, O., Papadopoulou, P., Slütter, B., & Kros, A. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103041 · Cited by 28
mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy
Shariati, A., Khani, P., Nasri, F., Afkhami, H., Khezrpour, A., Kamrani, S., Shariati, F. S., Alavimanesh, S., & Modarressi, M. H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00692-9 · Cited by 27
Martini 3 Building Blocks for Lipid Nanoparticle Design
Kjølbye, L. R., Valério, M., Paloncýová, M., Borges-Araújo, L., Pestana-Nobles, R., Grünewald, F., Bruininks, B. M. H., Araya‐Osorio, R., Šrejber, M., Mera‐Adasme, R., et al. (2025) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.5c01207 · Cited by 28
Antigen transfer and its effect on vaccine-induced immune amplification and tolerance
Shi, Y., Lu, Y., & You, J. (2022) · Theranostics · doi:10.7150/thno.75904 · Cited by 27
Lipid nanoparticle screening in nonhuman primates with minimal loss of life
Zenhausern, R., Jang, B., Echeverri, E. S., Gentry, K., Calkins, R., Curran, E. H., Wood, J., Stammen, R. L., Loughrey, D., Chappa, P., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02711-y · Cited by 29
Bates, S. M., Munson, M. J., Trovisco, V., Pereira, S. G. T., Miller, S. R., Sabirsh, A., Betts, C. J., Blenke, E. O., & Gay, N. J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114047 · Cited by 26
Bailey‐Hytholt, C. M., Ghosh, P., Dugas, J., Zarraga, I. E., & Bandekar, A. (2021) · Journal of Visualized Experiments · doi:10.3791/62226 · Cited by 27
In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?
Esteban, I., Pastor-Quiñones, C., Usero, L., Plana, M., García, F., & Leal, L. (2021) · Viruses · doi:10.3390/v13030501 · Cited by 26
Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics
Cerqueira, M. C., Belmonte‐Reche, E., Gallo, J., Baltazar, F., & Bañobre‐López, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030506 · Cited by 27
Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants
Liu, C., Rcheulishvili, N., Shen, Z., Papukashvili, D., Xie, F., Wang, Z., Wang, X., He, Y., & Wang, P. G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051101 · Cited by 27
Goldman, R., Murthy, N. T. V., Trent, N., Balakrishnan, A., Chivukula, S. V., Danz, H., Tibbitts, T. J., Dias, A., Vargas, J., Cooper, D. L., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122243 · Cited by 26
Smart CAR-T Nanosymbionts: archetypes and proto-models
Baena, J. C., Victoria, J. S., Toro-Pedroza, A., Aragón, C. C., Ortiz‐Guzman, J., García-Robledo, J. E., Torres, D., Ríos-Serna, L. J., Albornóz, L. L., Rosales, J. D., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1635159 · Cited by 27
Nonclinical safety evaluation of a novel ionizable lipid for mRNA delivery
Broudic, K., Amberg, A., Schaefer, M. K., Spirkl, H.-P., Bernard, M., & Désert, P. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116143 · Cited by 25
Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species
Peng, L., Fang, Z., Renauer, P. A., McNamara, A., Park, J. J.-Y., Lin, Q., Zhou, X., Dong, M. B., Zhu, B., Zhao, H., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111160 · Cited by 26
Safe and Effective Delivery of mRNA Using Modified PEI-Based Lipopolymers
Wang, H., Liu, X., Ai, X., Remant-Bahadur, K. C., Dick, T. A., Yan, B., Lu, T., Zhou, X., Luo, R., Liu, M., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020410 · Cited by 25
The design, manufacture and LNP formulation of mRNA for research use
Leighton, L. J., Chaudhary, N., Tompkins, H. E., Kulkarni, A., Carrodus, N. L., Budzinska, M. A., Das, S. L., Cheetham, S. W., & Mercer, T. R. (2025) · Nature Protocols · doi:10.1038/s41596-025-01174-4 · Cited by 24
Recent Advances in Lipid Nanoparticles: Nucleic Acid Therapeutics and Targeting Strategies
Sarmah, S., Baidya, S., & De, M. (2025) · Small · doi:10.1002/smll.202506812 · Cited by 25
COVID-19 Vaccines: Current Conditions and Future Prospects
Zieneldien, T., Kim, J., Cao, J. A., & Cao, C. (2021) · Biology · doi:10.3390/biology10100960 · Cited by 24
Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited]
Jawalagatti, V., Kirthika, P., & Lee, J. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884862 · Cited by 24
Ji, A., Xu, M., Pan, Y., Diao, L., Ma, L., Li, Q., Cheng, J., & Liu, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03445-1 · Cited by 24
Phosphatidylcholine Liposomes Reprogram Macrophages toward an Inflammatory Phenotype
Cauvi, D. M., Hawisher, D., Derunes, J., & Maio, A. D. (2023) · Membranes · doi:10.3390/membranes13020141 · Cited by 24
Zamani, P., Mashreghi, M., Bazaz, M. R., Zargari, S., Alizadeh, F. L., Dorrigiv, M., Abdoli, A., Aminianfar, H., Hatamipour, M., Zarqi, J., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.025 · Cited by 24
Distinct dynamics of mRNA LNPs in mice and nonhuman primates revealed by in vivo imaging
Lemdani, K., Marlin, R., Mayet, C., Perkov, V., Pascal, Q., Ripoll, M., Relouzat, F., Dhooge, N., Bossevot, L., Dereuddre‐Bosquet, N., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00900-5 · Cited by 25
Optimization of lipid nanoparticles for gene editing of the liver via intraduodenal delivery
Zhu, Y., Cai, S. S., Ma, J., Cheng, L., Wei, C. Y., Aggarwal, A., Toh, W. H., Shin, C., Shen, R., Kong, J., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122559 · Cited by 23
Lv, B., Zhao, Y., Liang, Y., & Cao, J. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.155438 · Cited by 23
Schultz, D. P., Münter, R., Cantín, A. M., Kempen, P. J., Jahnke, N., Andresen, T. L., Simonsen, J. B., & Urquhart, A. J. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114571 · Cited by 23
The Progress and Evolving Trends in Nucleic-Acid-Based Therapies
Liu, Y., Wang, C., Fu, X., & Ren, M. (2025) · Biomolecules · doi:10.3390/biom15030376 · Cited by 24
Hanna, A. R., Shepherd, S. J., Datto, G. A., El-Mayta, R., Anderson, T., Navarro, I. B., Ricciardi, A. S., Padilla, M. S., Srikumar, N., Zhang, S., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c15613 · Cited by 15
Cao, H., Wang, Y., Luan, N., & Liu, C. (2021) · Vaccines · doi:10.3390/vaccines9040310 · Cited by 23
Nanomedicine for the Delivery of RNA in Cancer
Ghidini, M., Silva, S. G., Evangelista, J., Vale, M. L. C., Farooqı, A. A., & Pinheiro, M. (2022) · Cancers · doi:10.3390/cancers14112677 · Cited by 23
Huang, L., Zhao, F., He, M., Fang, Y., Ma, X., Lu, S., Li, E., Xiao, H. Q., Zhu, H., Wang, X., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.002 · Cited by 23
Hendricks, G. G., Grigoryan, L., Navarro, M. J., Catanzaro, N., Hubbard, M. L., Powers, J. M., Mattocks, M. D., Treichel, C., Walls, A. C., Lee, J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu2085 · Cited by 24
Brain safety concerns of nanomedicines: The need for a specific regulatory framework
Szabat-Iriaka, B., & Borgne, M. L. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.06.011 · Cited by 22
mRNA-Based Approaches to Treating Liver Diseases
Cacicedo, M. L., Limeres, M. J., & Gehring, S. (2022) · Cells · doi:10.3390/cells11203328 · Cited by 23
Burdette, D. S., Ci, L., Shilliday, B., Slauter, R., Auerbach, A. D., Kenney, M., Almarsson, Ö., Cheung, E., & Hendrick, T. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.001194 · Cited by 22
Self-citationLi, J., Hu, J., Jin, D., Huo, H., Chen, N., Lin, J., & Lu, X. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02919-1 · Cited by 24
Zhao, H., Ma, S., Qi, Y., Gao, Y., Zhang, Y., Li, M., Chen, J., Song, W., & Chen, X. (2024) · Materials Horizons · doi:10.1039/d3mh02066e · Cited by 21
Advances in the study of LNPs for mRNA delivery and clinical applications
Wang, B., Shen, B., Xiang, W., & Shen, H. (2024) · Virus Genes · doi:10.1007/s11262-024-02102-6 · Cited by 22
Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines
Hauguel, T., Sharma, A. M., Mastrocola, E., Lowry, S., Maddur, M. S., Hu, C. H., Rajput, S., Vitsky, A., Choudhary, S., Manickam, B., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00980-3 · Cited by 21
Bellato, F., Feola, S., Verde, G. D., Bellio, G., Pirazzini, M., Salmaso, S., Caliceti, P., Cerullo, V., & Mastrotto, F. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00993 · Cited by 21
Du, X., Yada, E., Terai, Y., Takahashi, T., Nakanishi, H., Tanaka, H., Akita, H., & Itaka, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092291 · Cited by 21
Suzuki, Y., Katsurada, Y., & Hyodo, K. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00547 · Cited by 23
A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections
Wu, N., Zhang, J., Shen, Y., Zhang, X., Zhou, J., Wu, Y., Li, E., Meng, X., Chuai, X., Chiu, S., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.02.011 · Cited by 22
Recent Findings on Therapeutic Cancer Vaccines: An Updated Review
Sheikhlary, S., Lopez, D. H., Moghimi, S., & Sun, B. (2024) · Biomolecules · doi:10.3390/biom14040503 · Cited by 22
Nelson, A. L., Mancino, C., Gao, X., Choe, J. A., Chubb, L. S., Williams, K. B., Czachor, M. E., Marcucio, R., Taraballi, F., Cooke, J. P., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.05.020 · Cited by 21
Wang, W., Deng, S., Lin, J., & Ouyang, D. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.06.011 · Cited by 21
Rahamimov, N., Baturov, V., Shani, A., Ben-Zoor, I., Fischer, D., & Chernihovski, A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.081 · Cited by 21
Endothelial FOXM1 and Dab2 promote diabetic wound healing
Bhattacharjee, S., Gao, J., Lu, Y. W., Eisa-Beygi, S., Wu, H., Li, K. S., Birsner, A. E., Wong, S., Song, Y., Shyy, J. Y.-J., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.186504 · Cited by 21
Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis
Voss, C. J. D., Marcellus, Li, S., Ateere, A., McShane, H., & Stylianou, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1540359 · Cited by 20
Therapeutic circRNA aptamer alleviates PKR-associated osteoarthritis
Guo, S.-K., Suo, J., Huang, Y., Yin, X., Wang, J., Li, L., Sun, S., Zou, W., & Chen, L. (2025) · 中国科学通报：英文版 · doi:10.1016/j.scib.2025.02.027 · Cited by 20
mRNA delivery systems 2.0: Engineering extrahepatic delivery for non-vaccine therapeutics
Dalabehera, M., Ghosh, A., Mohanty, S., Chellappan, D. K., Chaudhari, S., Ale, Y., Poonia, N., Subudhi, R. N., Khanna, M., & Lim, H. G. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102584 · Cited by 22
Polymer-hybrid nanosystems for antiviral applications: Current advances
Soares, D. C. F., Poletto, F. S., Eberhardt, M. J., Domingues, S. C., Sousa, F. B. D., & Tebaldi, M. L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112249 · Cited by 22
Material Design for Next-Generation mRNA Vaccines Using Lipid Nanoparticles
Higuchi, A., Sung, T., Wang, T., Ling, Q., Kumar, S. S., Hsu, S.-T., & Umezawa, A. (2022) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2022.2106490 · Cited by 21
Yavuz, A., Coiffier, C., Garapon, C., Gürcan, S., Monge, C., Exposito, J., Arruda, D. C., & Verrier, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15031009 · Cited by 23
The Effect of Cholesterol Content on the Adjuvant Activity of Nucleic-Acid-Free Lipid Nanoparticles
Anindita, J., Tanaka, H., Yamakawa, T., Sato, Y., Matsumoto, C., Ishizaki, K., Oyama, T., Suzuki, S., Ueda, K., Higashi, K., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020181 · Cited by 21
Intracellular RNA delivery by lipid nanoparticles: Diffusion, degradation, and release
Zhdanov, V. P. (2019) · Biosystems · doi:10.1016/j.biosystems.2019.104032 · Cited by 21
Recent Advances in mRNA-LNP Delivery Systems for Extrahepatic Organs: A Review
Bai, Y., Cui, L., Liu, T., Wang, Z., Cao, H., He, S., Qiu, J., Li, Y., Zhou, Y., Shi, J., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00385 · Cited by 23
Lipid nanoparticle-mediated delivery of microRNA-124 reduces neuroinflammation
Ma, Z., Dang, H. A., Yang, J., Rodella, G., Mwema, A., Lombaerde, E. D., Chen, Y., Geest, B. G. D., Pesch, V. V., Muccioli, G. G., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123589 · Cited by 19
Small interference ( RNAi ) technique: Exploring its clinical applications, benefits and limitations
Redhwan, M. A. M., Hariprasad, M. G., Samaddar, S., Hard, S. A. A. A., Yadav, V., Mukherjee, A., & Kumar, R. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14039 · Cited by 19
Zhang, P., Falcone, S., Tsybovsky, Y., Singh, M., Gopan, V., Miao, H., Seo, Y., Rogers, D., Renzi, I., Lai, Y., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305896120 · Cited by 19
Self-citationHPV16 E6/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions
Zhou, K., Yuzhakov, O., Behloul, N., Wang, D., Bhagat, L., Chu, D., Zhang, X., Cheng, X., Fan, L., Huang, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213285 · Cited by 20
Self-citationMachado, R. R. G., Walker, J. L., Scharton, D., Rafael, G. H., Mitchell, B. M., Reyna, R. A., de Souza, W. M., Liu, J., Walker, D. H., Plante, J. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40033-2 · Cited by 15
Allen, J. D., & Ross, T. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1334670 · Cited by 19
Metadata
- Authors
- Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., Mihai, C., Lynn, A., McFadyen, I., Moore, M. J., Senn, J. J., Stanton, M. G., Almarsson, Ö., Ciaramella, G., & Brito, L. A.
- Affiliations
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Brito, Luis A.
- ORCID
- Venue
- Molecular Therapy — Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 15
- Pages
- 1-11
- ISSN
- 2162-2531 (ISSN-L)
- PMC
- PMC6383180
- OpenAlex
- W2914060533
- Cited by
- 927
- References
- 35
- Citations by year
- 2026: 141 · 2025: 202 · 2024: 162 · 2023: 140 · 2022: 128 · 2021: 114 · 2020: 35 · 2019: 5
- FWCI
- 23.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecular Therapy — Nucleic Acids (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Moderna Therapeutics
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- lipid nanoparticles, mRNA vaccines, intramuscular administration, ionizable lipids, biodegradable lipids, immunogenicity, tolerability, innate immune activation, non-human primates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
